Atlas Venture

Daily

J&J and Atlas Venture back launch of drug developer using epigenetics to treat Alzheimer’s disease

Johnson & Johnson (NYSE: JNJ) kicked off the launch of its Boston innovation center with news that it is backing a new drug developer targeting Alzheimer’s disease and other neurological disorders. Early stage life science investor Atlas Venture started Rodin Therapeutics with biotechnology company Proteros and secured backing from J&J’s venture arm. Rodin is using epigenetics […]